Syndeio Biosciences, Inc

Quick facts

Phase 2 pipeline

• AGN-241751 · Cardiovascular
  AGN-241751 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Syndeio Biosciences, Inc portfolio CI brief
• Syndeio Biosciences, Inc pipeline updates RSS